Staidson Biopharmaceuticals Hits Day Low at CNY 23.41 Amid Price Pressure

Staidson (Beijing) Biopharmaceuticals Co., Ltd. experienced a notable decline today, with the stock dropping by 3.31% on June 2, 2026. The stock reached an intraday low of CNY 23.41, reflecting ongoing challenges within the company. Over the past month, Staidson has seen a significant decrease of 13.39%, while its year-to-date performance stands at a decline of 12.41%. In comparison, the China Shanghai Composite index has shown a modest gain of 0.43% today, highlighting Staidson's underperformance relative to the broader market. The company has faced persistent difficulties, reporting negative net sales growth of 10.84% annually over the last five years and experiencing losses for six consecutive quarters. Staidson's financial metrics indicate a low return on capital employed (ROCE) of 0% and a negative return on equity of 11.48%. With a market capitalization of CNY 12,734 million, the company operates within the pharmaceuticals and biotechnology sector, but its current financial health raises concerns about its future viability.